Patient
Guidance

 

What do my patients need to know?

In order to keep patients at ease, it should be ensured that they too understand the purpose of biomarker testing for non-small cell lung cancer (NSCLC), and the reasons behind the different testing methods.

For the benefit of the patient, testing should be conducted in the shortest possible timeframe so that treatment decisions can be made quickly.

 

Sample options for mutation testing

EGFR Mutation

ctDNA, circulating tumour DNA; EGFR, epidermal growth factor receptor

The most suitable sample type for testing will depend in part on the time point of testing and on availability of samples

Initial Testing (Diagnosis)

Preferences for tumour tissue

Tissue samples may already be available (i.e. for establising a diagnosis of lung cancer)

Both recent and Archival tissue (up to 3 years old) can be used to test for programmed cell death-ligand 1 (PD-L1) testing, as well as primary or metastatic lesions6,7

Testing on Progression

If tissue is not available, preference for plasma ctDNA

Involves non-invasive methods (i.e. blood test)

Biopsy samples can be difficult to obtain in patients with advanced disease

Plasma sampling is quicker and cheaper than biopsy

X


NSCLC patient

NSCLC patient

Read more
Nurse/patient

Nurse/patient

Read more
LVNG With lung cancer

LVNG With lung cancer

Read more
Patient support group

Patient support group

Read more